Abstract
BACKGROUND. In December 2019, cases of pneumonia of unknown etiology were detected in Wuhan (China), and later a new type of coronavirus was identified – SARS-CoV-2. In March 2020, spread of the SARS-CoV-2 was officially recognized as a pandemic.
OBJECTIVE. To demonstrate to the doctors of the thoracic surgery and pulmonology departments our experience in the tactics of treating subpleural and intrapulmonary hematomas, which is a consequence of a coronavirus infection, and determining the need for surgical intervention.
MATERIALS AND METHODS. From the beginning of the COVID-19 pandemic on the basis of the clinical department of the surgical treatment of tuberculosis and non-specific diseases complicated by purulent-septic infections of the SI “National Institute of Phthisiology and Pulmonology named after F.G. Yanovsky of the NAMS of Ukraine” treated 11 patients with spontaneous hematomas of post-COVID genesis, of which subpleural hematomas accounted for 9 cases (81.8 %), and intrapulmonary – 2 (18.2 %). The distribution by gender was as follows: 7 (63.6 %) women were treated, and 4 (36.4 %) men. The age of the patients ranged from 28 to 70 years, the average age was 45 years. This group of patients had the following associated pathologies: chronic obstructive pulmonary disease – 3 (27.3 %), hypertension – 3 (27.3 %), diabetes – 2 (18.2 %), chronic renal failure – 1 (9.0 %), ischemic heart disease – 2 (18.2 %).
CONCLUSIONS. Lack of timely diagnosis and surgical treatment of subpleural and intrapulmonary hematomas often leads to the addition of secondary infection, which complicates the treatment process.
Publisher
Communicable Diseases Intensive Care Association